Cardiac Amyloidosis is an infiltrative cardiomyopathy in which abnormal ... requiring only a single apical 4-chamber echo video clip. Ultromics' medical devices are software-only, manufactured ...
and amyloid-cardiomyopathy). New York Heart Association (NYHA) Class ≥ II at screening. Adequate acoustic windows for echocardiography. Participants on beta blockers, verapamil, diltiazem, or ...
Vutrisiran, a transthyretin-directed small interfering RNA therapeutic, is currently approved under the brand name Amvuttra ® for the treatment of polyneuropathy manifestations of hereditary ...
BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...
The Food and Drug Administration (FDA) has approved Attruby TM (acoramidis) for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...
Acoramidis becomes the second drug ever approved for this condition, based on the results of the ATTRibute-CM trial.
Discover how kidney function decline in ATTR-CM patients predicts higher mortality, highlighting its role as a critical marker in disease management and care optimisation.
On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback